InsiderPulseNo transactions found.
| Date | Member | Chamber | Type | Amount |
|---|---|---|---|---|
| 2025-10-20 | Debbie Wasserman Schultz(D-FL25) | house | Sale | $2,000.00 |
| 2025-07-16 | Debbie Wasserman Schultz(D-FL25) | house | Sale | $1,001 - $15,000 |
| 2025-06-27 | Debbie Wasserman Schultz(D-FL25) | house | Purchase | $1,001 - $15,000 |
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Net sales | $292.5M-3.8% | $303.9M-10.3% | $338.8M+7.1% | $316.2M+8.7% | $291.0M |
| Cost of sales (exclusive of intangible amortization) | $134.8M-9.7% | $149.2M-9.3% | $164.5M+9.3% | $150.5M+12.1% | $134.2M |
| Gross margin | $157.7M+1.9% | $154.7M-11.2% | $174.2M | — | — |
| Research and development | $26.2M-16.8% | $31.5M+5.5% | $29.9M-2.8% | $30.7M-15.5% | $36.4M |
| Sales and marketing | $103.1M+0.3% | $102.8M-1.4% | $104.2M+9.4% | $95.3M+17.2% | $81.3M |
| General and administrative | $42.1M+2.3% | $41.2M+2.9% | $40.0M+4.0% | $38.5M+7.1% | $35.9M |
| Amortization of intangibles | $10.3M-20.9% | $13.0M-30.6% | $18.8M-3.4% | $19.5M+7.3% | $18.1M |
| Goodwill impairment | $0-100.0% | $159.5M+996.1% | $14.5M | $0 | $0 |
| Change in fair value of contingent consideration | $272K-37.0% | $432K-81.4% | $2.3M+91.4% | $1.2M+1261.8% | $89K |
| Acquisition, restructuring and other items, net | $15.6M-70.6% | $53.2M+240.2% | $15.6M+72.9% | $9.0M-55.3% | $20.2M |
| Total operating expenses | $197.7M-50.8% | $401.6M+78.2% | $225.4M+16.1% | $194.2M+1.1% | $192.1M |
| Gain on sale of assets | $0-100.0% | $54.5M | $0 | $0 | — |
| Operating loss | -$40.0M+79.2% | -$192.4M-276.0% | -$51.2M-79.8% | -$28.5M+19.3% | -$35.3M |
| Interest income (expense), net | $978K-39.4% | $1.6M+159.7% | -$2.7M-292.7% | -$688K | — |
| Other income (expense), net | $4.9M+705.1% | -$817K-47.5% | -$554K | — | $92K |
| Total other income (expense), net | $5.9M+643.0% | $797K+124.5% | -$3.3M-120.3% | -$1.5M | — |
| Loss before income tax benefit | -$34.0M+82.2% | -$191.6M-252.0% | -$54.4M | — | -$36.1M |
| Income tax benefit | -$39K+99.5% | -$7.3M-265.4% | -$2.0M+41.4% | -$3.4M+24.5% | -$4.5M |
| Net loss | -$34.0M+81.6% | -$184.3M-251.5% | -$52.4M-97.5% | -$26.5M+15.9% | -$31.5M |
| Basic (usd per share) | -$830+81.9% | -$5K-245.1% | -$1K-95.6% | -$680-82826.8% | -$0.82 |
| Diluted (usd per share) | -$830+81.9% | -$5K-245.1% | -$1K-95.6% | -$680-82826.8% | -$0.82 |
| Basic (in shares) | $40.85B+1.7% | $40.18B+1.8% | $39.48B+1.2% | $39.01B+101639.4% | $38.3M |
| Diluted (in shares) | $40.85B+1.7% | $40.18B+1.8% | $39.48B+1.2% | $39.01B+101639.4% | $38.3M |
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
Wall Street Analysts Believe AngioDynamics (ANGO) Could Rally 65.75%: Here's is How to Trade
AngioDynamics CEO Touts Debt-Free Turnaround, Auryon Share Gains, NanoKnife Launch at Needham Conf
AngioDynamics (ANGO) Loses 5.8% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
AngioDynamics (ANGO) Upgraded to Buy: Here's Why